Box Layout

HTML Layout
Backgroud Images
Backgroud Pattern
  • E-mail : info_medicalmarketing@jindunmedical.com
  • Phone : +86 21 64057580
  • Address : Shanghai China

Pregabalin, gabapentin... They should not be used for chronic low back pain

  • 2022-12-06
  • JINDUN MEDICAL

Pregabalin and gabapentin are anticonvulsants with a clear role in the management of long-term conditions such as epilepsy, postherpetic neuralgia, and neuropathic pain.

LUE LISÄÄ

What is the Difference Between API and Intermediate?

  • 2022-12-05
  • JINDUN MEDICAL

From the perspective of new drug development, an API is a compound that can be safely used in the human body for therapeutic diagnosis after sufficient pharmaceutical research.

LUE LISÄÄ

Is gabapentin effective in treating neuropathic eye pain due to dry eye?

  • 2022-12-05
  • JINDUN MEDICAL

Dry eye is a common cause of chronic eye pain, which is associated with ocular discomfort, pain and visual impairment due to tear dysfunction and ocular surface injury.

LUE LISÄÄ

Decoding Guobang Pharmaceuticals 2022 quarterly report: pharmaceutical platform leading development momentum, hands on API to accelerate globalization layout

  • 2022-12-05
  • JINDUN MEDICAL

As medical reform continues to deepen, under the influence of policy support, more and more pharmaceutical companies are relying on their own construction to carry out "large and c

LUE LISÄÄ

Relationship between engramine treatment and uric acid levels and prognosis in patients with heart failure with reduced ejection fraction

  • 2022-12-02
  • JINDUN MEDICAL

Hyperuricemia is a common symptom in patients with heart failure (HF) and can lead to an increased risk of HF hospitalization and increased mortality. Therefore, serum uric acid (S

LUE LISÄÄ

12 drug companies on the blacklist, 46 drug companies products were withdrawn from the network qualification

  • 2022-12-02
  • JINDUN MEDICAL

Involved in the failure to fulfill the relevant obligations, violation of the financial system, etc.

LUE LISÄÄ

Market Development Overview of China Para-Aminophenol Industry in 2022

  • 2022-12-01
  • JINDUN MEDICAL

According to the published "China p-aminophenol Market Research and Investment Value Report (2022 Edition)": p-aminophenol, also known as p-hydroxyaniline, is an important fine che

LUE LISÄÄ

Analysis of the demand for p-aminophenol API in India during the epidemic period

  • 2022-11-30
  • JINDUN MEDICAL

China is the world's largest API producer and exporter of para-aminophenol raw materials, and India is the number one importer of the product, accounting for 65%-75% of China&#

LUE LISÄÄ

A cross-sectional survey of self-medication with Traditional Chinese Medicine for treatment and prevention of COVID-19.

  • 2022-11-29
  • JINDUN MEDICAL

Self-medication with TCM during the COVID-19 pandemic for symptom control or prevention is prevalent.

LUE LISÄÄ

Green diastereospecific synthesis of various medicine analogues containing dipeptides and release of the medicines by Baker's yeast

  • 2022-11-29
  • JINDUN MEDICAL

We have succeeded green and economical synthesis of various dipeptides in 76–99% yields with 70–>99% de and dipeptides-containing medicine analogues in 74–99% yields with 79–97% de

LUE LISÄÄ